Imara Agrees to Sell Tovinontrine to Cardurion
Imara has agreed to sell to Cardurion Pharmaceuticals its phosphodiesterase (PDE9) inhibitor tovinontrine (IMR-687) and all other assets related to its PDE9 program.
The decision follows Imara’s disappointing results from two clinical trials of tovinontrine in patients with beta thalassemia, a blood disorder that reduces the production of hemoglobin.
The drug failed to show meaningful improvements in the endpoints of total hemoglobin, transfusion burden, vaso-occlusive crises and fetal hemoglobin response.
The aggregate purchase price for Imara’s PDE9 assets includes an upfront cash payment of about $34.7 million, plus possible future payments of up to $60 million if certain milestones are achieved.